Biofarma is acquiring 100% of US Pharma Lab in a strategic partnership. The deal involves reinvestment from US Pharma Lab's founders, Ashok Luhadia (Chairman) and Amol Luhadia (CEO), and other family members into Biofarma Group's parent company. US Pharma Lab is a leading CDMO specializing in nutraceutical products such as probiotics, vitamins, and supplements, with operations in the US and China.
This acquisition marks Biofarma Group's transformation into the first global CDMO exclusively focused on nutraceuticals. With a production footprint in the US, Europe (Italy and France), and China, they offer strong innovation capabilities on both sides of the Atlantic, focusing on probiotics and other nutraceuticals, and serving pharma clients, CPGs, and digitally native brands.
Gianfranco Nazzi, CEO of Biofarma Group, is excited about the partnership, expecting significant benefits for customers through expanded nutraceutical technologies and R&D capabilities on a global scale.
Amol Luhadia, CEO of US Pharma Lab, is confident in the acquisition's success, believing that Biofarma Group's entrepreneurial and innovative culture aligns well with US Pharma Lab's core values and ability to deliver differentiated solutions.
The acquisition, subject to customary closing conditions, will be completed in Q3 of 2023. Afterward, Amol Luhadia and the management team will continue to lead US Pharma Lab in the US, with Amol Luhadia joining the Biofarma Group Board and Ashok Luhadia becoming Chairman Emeritus of US Pharma Lab. The partnership aims to create a formidable presence in the nutraceutical industry.
#Business #Italy #France #US #Europe #nutraceutical #products #probiotics #vitamins #supplements #footprint #technologies #solutions #technology #acquistion
